Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.
Combining the pan-deacetylase inhibitor panobinostat with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.
Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC).
Adding the VEGFR-2 inhibitor ramucirumab (Cyramza) to standard docectaxel improved overall survival (OS) by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer (NSCLC).
The dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate.
RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for panitumumab in mCRC, according to an analysis of phase III, second-line data, which are consistent with previously reported data in first-line mCRC.
Salvage therapy combining the novel Hsp90 inhibitor ganetespib with docetaxel significantly improved OS in some patients with NSCLC in the phase IIb/III GALAXY- 1 trial.